Eucrates Biomedical Acquisition Corp (EUCR) Financials
$10.04
$0.00 (0.00%)As on 05-May-2023 09:30EDT
Market cap
$42 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
47.8
P/B Ratio
0.4
Div. Yield
0 %
Cashflow ($ Mln) |
TTM | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Dec-14 | Dec-13 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Cash From Operating Activities
|
--
|
-0.63
|
-0.50
|
-1.71
|
--
|
--
|
|||||
|
Cash Flow from Investing Activities
|
--
|
93.19
|
--
|
-314.39
|
--
|
--
|
|||||
|
Cash from Financing Activities
|
--
|
-92.59
|
3.60
|
317.75
|
--
|
--
|
|||||
|
Net Cash Inflow / Outflow
|
--
|
-0.03
|
3.09
|
--
|
--
|
--
|
Financials Ratios |
TTM | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Dec-14 | Dec-13 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Adjusted EPS ($)
|
--
|
1.85
|
0.00
|
--
|
--
|
--
|
|||||
|
Cash EPS ($)
|
--
|
1.85
|
0.00
|
--
|
--
|
--
|
|||||
|
Adjusted Book Value ($)
|
--
|
2.85
|
33.10
|
--
|
--
|
--
|
|||||
|
Dividend per Share ($)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Cash Flow per Share ($)
|
--
|
-0.21
|
-0.17
|
--
|
--
|
--
|
|||||
|
Free Cash Flow per Share ($)
|
--
|
-0.21
|
-0.17
|
--
|
--
|
--
|
Profitability Ratios |
TTM | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Dec-14 | Dec-13 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
ROCE (%)
|
--
|
10.26
|
0.01
|
--
|
--
|
--
|
|||||
|
ROE (%)
|
3.64
|
10.27
|
0.01
|
--
|
--
|
--
|
|||||
|
ROA (%)
|
4.76
|
9.42
|
0.01
|
--
|
--
|
--
|
|||||
|
EBIT Margin (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Net Margin (%)
|
287.78
|
177.60
|
0.19
|
--
|
--
|
--
|
|||||
|
Cash Profit Margin (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
Growth Ratios |
TTM | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Dec-14 | Dec-13 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Revenue Growth (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
EBIT Growth (%)
|
-127.29
|
-8,228.67
|
101.90
|
--
|
--
|
--
|
|||||
|
Net Profit Growth (%)
|
7.84
|
64,337.84
|
--
|
--
|
--
|
--
|
|||||
|
EPS Growth (%)
|
--
|
643.30
|
--
|
--
|
--
|
--
|
|||||
|
Book Value Growth (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
Valuation Ratios |
TTM | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Dec-14 | Dec-13 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Price / Earnings
|
47.81
|
5.41
|
3,407.03
|
--
|
--
|
--
|
|||||
|
Price / Book Value
|
0.41
|
3.51
|
0.29
|
--
|
--
|
--
|
|||||
|
Dividend Yield (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
EV/EBITDA
|
-62.64
|
-6.86
|
16.71
|
--
|
--
|
--
|
|||||
|
Close Price ($)
|
10.14
|
9.99
|
9.76
|
10.05
|
--
|
--
|
|||||
|
High Price ($)
|
10.25
|
10.07
|
10.88
|
10.18
|
--
|
--
|
|||||
|
Low Price ($)
|
9.84
|
9.75
|
9.59
|
10.00
|
--
|
--
|
|||||
|
Market Cap ($ Cr)
|
42.23
|
--
|
--
|
--
|
--
|
--
|
Solvency Ratios |
TTM | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Dec-14 | Dec-13 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Debt to Equity
|
--
|
0.01
|
--
|
--
|
--
|
--
|
|||||
|
Short term debt to equity ratio
|
0.01
|
0.01
|
--
|
--
|
--
|
--
|
|||||
|
Current Ratio
|
2.03
|
2.03
|
6.87
|
19.42
|
--
|
--
|
|||||
|
Quick Ratio
|
2.03
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Interest Coverage
|
1.79
|
-0.22
|
0.00
|
--
|
--
|
--
|
Operating Efficiency Ratios |
TTM | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | Dec-14 | Dec-13 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Debtors to sales (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Asset Turnover
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Receivable days
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Inventory Days
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Payable days
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Cash Conversion Cycle
|
--
|
--
|
--
|
--
|
--
|
--
|